ClinicaliQ Trial Snapshot
- A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy — Active Not Recruiting • Phase III •….
- A new drug combination (ceralasertib plus durvalumab) tested against standard chemotherapy in advanced lung cancer patients whose disease progressed despite previous immunotherapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy. Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer Interventions: Ceralasertib, Durvalumab, Docetaxel Lead Sponsor: AstraZeneca Planned Enrollment: 594 participants